Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lipeng Xue
Institutions:
First Affiliated Hospital of Guangzhou Medical University,
State Key Laboratory of Respiratory Disease,
Guangzhou Institute of Respiratory Health
Observed institutions:
First Affiliated Hospital of Guangzhou Medical University,
Guangzhou Medical University Cancer Hospital,
State Key Laboratory of Respiratory Disease,
Guangzhou Institute of Respiratory Health
ORCID:
0009-0006-4693-4396
Observed ORCID:
0009-0006-4693-4396
OpenAlex ID:
A5100584819
Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis
2024
·
Dandan Ding
, Chenguang Xu
, et al.
·
Translational Oncology
·
12
Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study
2026
·
Xiaohuan Zhou
, Yi Feng
, et al.
·
Lung Cancer
·
1
First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors
2026
·
Lipeng Xue
, Yi Feng
, et al.
·
Lung Cancer
Show more works
View as search
Works count:
3
Citation count:
13
H-index:
1
I10-index:
1
Year
Topic
Type